Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

The UK's drugs regulator—the MHRA—has approved the Alzheimer's drug donanemab, but it won't be available on the NHS.

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...